Clinical Trials · NCT06473259

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Name: Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingN/AGonadorelin

Phase: N/A
Recruitment status: Recruiting
Sponsor: Santa Chiara Hospital
Enrollment: 3,000
Start date: Dec 2016
Locations: 3 sites, Italy
Primary endpoint: progression free survival

View Gonadorelin compound reference